StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

Stock analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Wednesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Trading Down 2.6 %

TXMD stock opened at $1.11 on Wednesday. TherapeuticsMD has a 52 week low of $0.70 and a 52 week high of $2.75. The firm has a 50 day moving average of $1.29 and a 200 day moving average of $1.56.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP increased its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. 30.74% of the stock is owned by hedge funds and other institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.